Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a generally positive outlook with strong growth expectations for key products like AUSTEDO and UZEDY, a robust pipeline, and effective cost management strategies. However, management's cautious approach in providing specific guidance for certain products and data may limit the upside potential. The overall sentiment is positive, supported by optimistic guidance and strategic initiatives, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue $17.3 billion, a 5% increase year-over-year. Growth attributed to strong performance in innovative products and stable generics business.
EBITDA $5.3 billion, a 12% increase year-over-year. Growth driven by higher revenue and operational efficiencies.
EPS $2.93, a 19% increase year-over-year. Growth due to improved profitability and operational performance.
Free Cash Flow $2.4 billion, a 16% increase year-over-year. Growth supported by strong revenue and operational improvements.
Net Debt to EBITDA Ratio 2.5x, improved from previous levels. Progress towards the 2027 goal of 2x.
Innovative Portfolio Revenue (AUSTEDO, UZEDY, AJOVY) $3.1 billion, a 35% increase year-over-year. Growth driven by strong performance of AUSTEDO (up 34% to $2.26 billion), UZEDY (up 63% to $191 million), and AJOVY (up 30% to $673 million).
AUSTEDO Revenue $2.26 billion, a 34% increase year-over-year. Growth driven by new patients, better adherence, and increased milligram volume (19%).
UZEDY Revenue $191 million, a 63% increase year-over-year. Growth driven by expanding the long-acting injectable market and transitioning patients from oral therapies.
AJOVY Revenue $673 million, a 30% increase year-over-year. Growth driven by market share expansion, pricing management, and geographic expansion.
Generics Business Revenue Flat year-over-year. Stability achieved with a 2-year CAGR of 6%. U.S. grew 2%, international markets grew 1%, and Europe declined 2%.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Innovative Portfolio: AUSTEDO, UZEDY, and AJOVY achieved $3.1 billion in revenue, up 35%. AUSTEDO grew 34% to $2.26 billion, UZEDY grew 63% to $191 million, and AJOVY grew 30% to $673 million. AUSTEDO XR accounts for 60% of new patients.
Pipeline Developments: Filed olanzapine LAI, completed DARI study recruitment, and started Phase III for duvakitug in UC and CD. Pipeline has potential peak sales of over $10 billion.
Biosimilars Expansion: 10 assets launched globally, 6 more to launch by 2027, and another 10 from 2028 onwards. Expected to grow biosimilars business by $400 million by 2027.
Geographic Expansion: AJOVY leads in 30 markets across Europe and internationally. UZEDY is expanding the long-acting injectable market.
Revenue Growth: 2025 revenue increased 5% to $17.3 billion. EBITDA grew 12% to $5.3 billion, and free cash flow increased 16% to $2.4 billion.
Cost Savings: Transformation program aims for $700 million in net savings by 2027, with $70 million achieved in 2025.
Pivot to Growth Strategy: Focus on innovative biopharma transition, stable generics business, and capital allocation to high-return areas. Achieved 6% CAGR over 3 years.
Debt Reduction: Net debt reduced to $13 billion, with a net debt-to-EBITDA ratio of 2.5x, targeting 2x by 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: Potential challenges in obtaining approval for olanzapine LAI and other pipeline products, as regulatory processes can be complex and time-consuming.
Supply Chain Disruptions: No explicit mention of supply chain issues, but the reliance on biosimilars and innovative products could expose the company to potential disruptions in manufacturing or distribution.
Economic Uncertainties: The company faces revenue headwinds of approximately $1.1 billion from generic Revlimid in 2026, which could impact financial performance.
Strategic Execution Risks: The success of the Pivot to Growth strategy depends on achieving ambitious targets, such as $700 million in savings by 2027 and maintaining a 30% operating margin. Failure to execute these plans could adversely affect the company.
Market Conditions: The generics business remains flat, and the company faces pricing pressures and competition in the generics and biosimilars markets.
Competitive Pressures: The company is transitioning from a generics-focused business to a biopharma model, which involves competing with established players in the innovative drug market.
Financial Risks: The company has a high net debt of approximately $13 billion, which could pose risks if financial targets are not met or if economic conditions worsen.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
AUSTEDO Revenue Guidance: Guidance of $2.4 billion to $2.55 billion for 2026, with potential to hit $2.5 billion a year ahead of schedule.
UZEDY Revenue Guidance: Guidance of $250 million to $280 million for 2026, reflecting strong growth momentum.
AJOVY Revenue Guidance: Guidance of $750 million to $790 million for 2026, driven by market leadership and commercial excellence.
Pipeline Revenue Potential: The pipeline has a potential of over $10 billion in peak sales, with every product targeting markets of significant size and unmet medical needs.
Biosimilars Growth: On track to grow the biosimilars business by $400 million by 2027, with 6 additional launches by 2027 and 10 more assets launching from 2028 onwards.
2026 Revenue Guidance: Expected full-year revenue of $16.4 billion to $16.8 billion, reflecting 1% growth to 2% decline compared to 2025, excluding milestone payments and Japan business venture contributions.
Non-GAAP Gross Margin: Expected to be in the range of 54.5% to 55.5% for 2026, showing improvement driven by portfolio mix and cost savings.
Free Cash Flow: Expected to be in the range of $2 billion to $2.4 billion for 2026, with a strong improvement trajectory.
Long-Term Financial Targets: On track to achieve 30% non-GAAP operating margin by 2027, net debt-to-EBITDA ratio of 2x, and more than $3.5 billion in free cash flow by 2030.
Innovative Portfolio Growth: Continued strong momentum expected in innovative products like AUSTEDO, AJOVY, and UZEDY, driving higher margins and free cash flow.
Pipeline Milestones for 2026: Seven key milestones expected, including data readouts for duvakitug, anti-IL-15, and emrusolmin, as well as the anticipated approval of olanzapine LAI.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about net pricing dynamics and what's baked into your assumptions for AUSTEDO in 2026, and how should we think about volume growth?
A:Management highlighted strong fundamentals for AUSTEDO, including TRx growth, adoption of XR, and milligram growth at 19%. They emphasized disciplined pricing strategies despite increased competition and noted strong performance even after accounting for inventory build and gross-to-net adjustments. They expect growth in the range of 11% to 18% for 2026, factoring in potential Q4 destocking.
Q:How should we think about net pricing for UZEDY and the assumptions baked into your guidance?
A:Management noted strong TRx growth for UZEDY and acknowledged the mix of Medicaid and Medicare exposure, with one being more profitable than the other. They have factored this mix into their guidance and remain optimistic about the product's momentum.
Q:Where do you see the greatest disconnect between your pipeline excitement and what the Street is missing?
A:Management believes the speed and quality of their pipeline development, including antibodies and duvakitug, may have caught the market by surprise. They anticipate recognition as data emerges, citing external validation from partnerships and designations.
Q:How should we think about modeling AUSTEDO in 2027 in light of IRA and other factors?
A:Management reiterated their commitment to achieving $2.5 billion for AUSTEDO in 2027, with potential to reach this figure in 2026. They emphasized the significant opportunity in treating the 85% of tardive dyskinesia patients who remain untreated and highlighted the benefits of AUSTEDO XR for compliance and adherence.
Q:How are you thinking about funding R&D and balancing partnerships versus internal spend?
A:Management emphasized the importance of moving their pipeline quickly to market, noting that partnerships do not significantly impact economics due to the scale of potential revenues and the transformative effect on gross margins. They highlighted their ability to launch multiple products over a short period.
Q:What are your expectations for TL1A maintenance data compared to induction data?
A:Management expressed optimism, citing the potency, selectivity, and low antidrug antibodies of their TL1A antibody. They anticipate strong maintenance data based on the quality of their Phase II results and study execution.
Q:What is the gross margin outlook versus OpEx spend ratio for 2026?
A:Management expects gross margins in the range of 54.5% to 55.5% for 2026, with OpEx remaining in the 27% to 28% range. They plan to reduce G&A expenses and reallocate savings to R&D and sales and marketing.
Q:What can we expect from the upcoming Phase Ib vitiligo data?
A:The Phase Ib study will include 38 patients and measure facial VASI and total VASI scores, providing comparable data to other treatments. Management highlighted the potential for a systemic, quarterly subcutaneous treatment, addressing unmet needs in vitiligo.
Q:Can you elaborate on development timelines for IL-15 in vitiligo and celiac?
A:Management highlighted the potential for accelerated development in vitiligo due to clear regulatory endpoints and unmet needs. They also see opportunities in celiac and other indications, emphasizing the versatility of IL-15 as a cytokine.
Q:What drove the higher sales and marketing spend this quarter, and is the Royalty Pharma payment embedded in 2026 guidance?
A:Management attributed higher sales and marketing spend to investments in growth drivers like AUSTEDO and preparations for the olanzapine launch. They confirmed that $25 million of the Royalty Pharma payment is included in 2026 guidance, with no other milestones embedded.
Q:What is your R&D philosophy, and how much derisking will occur with upcoming data readouts?
A:Management emphasized a data-driven approach, focusing on known science and derisked assets. They highlighted their ability to pivot quickly based on data and anticipate significant derisking with upcoming readouts.
Q:Has your BD philosophy changed as you transition to a biopharma company?
A:Management remains disciplined in capital allocation, focusing on synergistic assets in CNS, neurology, and immunology. They noted increased interest from potential partners due to their commercial and R&D capabilities.
Q:What is the launch cadence and profitability profile for biosimilars, and what is your strategy for expanding the portfolio?
A:Management plans to launch six biosimilars between now and 2027, with most targeting both U.S. and European markets. They emphasized the accretive nature of partnerships and aim to expand their portfolio through collaborations with existing and new partners.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for AUSTEDO in 2027, stating they would discuss it next year. They also did not provide detailed expectations for TL1A maintenance data or specific comparisons to competitors. Additionally, they did not elaborate on the exact impact of rebate reversals versus inventory adjustments for AUSTEDO in Q1.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AUSTEDO AJOVY
AUSTEDO benefit
Crohn
Eli Kalif
Eli detail
II study
III program
III study
Phase II
Pivot
Revlimid
Teva
UC
UZEDY
adolescent
aim stability
asset
cost saving
course
credit rating
detail AUSTEDO
development milestone
end inventory
endpoint
finance
flow trajectory
inhaler fact
investment grade
migraine
milestone payment
momentum portfolio
payment contribution
pediatrics
pride
rating progress
response
result portfolio
result slide
tax
term target
TEVA Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call shows mixed results: a slight revenue increase and improved net income, but declining operating income and free cash flow. The lack of strategic updates and forward-looking risks add uncertainty. The absence of Q&A insights and market cap data further limits sentiment clarity. Overall, a neutral market reaction is expected.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
TEVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
